RevnaBio’s newly secured triple accreditation across ISO 15189, ISO 20387, and ISO/IEC 17043 marks a significant step in advancing clinical research in Africa. This milestone is poised to strengthen diagnostic quality and expand precision medicine on the continent.

The global clinical mass spectrometry market is expected to reach USD 3.31 billion by 2031, signaling a profound shift toward high-specificity diagnostics. Recent findings highlight this technology’s growing influence on clinical labs worldwide, positioning it for substantial expansion.

A new report from Exactitude Consultancy predicts that the molecular targeted therapy market will surpass $246 billion by 2034, marking significant growth in the healthcare sector.